CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (NASDAQ: ATHX) announced today that its partner, HEALIOS K.K. (Healios), has completed enrollment in its TREASURE study in Japan, evaluating MultiStem® (invimestrocel) cell therapy treatment in patients who have…
Athersys Partner HEALIOS K.K. Completes Enrollment in the TREASURE Study of MultiStem Treatment for Ischemic Stroke
Share this article
More News

Bitcoin Stuck Near $65K Because Capital Is Flowing to AI
July 23, 2026

3 golden investment rules immortalised by Warren Buffett
July 23, 2026



